Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Open Label Study of ONTAK® (Denileukin Diftitox, DAB389IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status
Brief Summary:
The purpose of this research study is to evaluate how effective ONTAK is in the treatment of cutaneous T-cell Lymphoma (CTCL) and determine whether the presence of a type of protein called CD25 on the cancer cells makes a difference in how the body responds to the treatment.
The hypothesis is that there is no difference in response rate for patients whose tumor cells are CD25 positive or negative.